A Clinical Study in Cancer Patients to Investigate the Potential Impact of Custirsen, on the Blood Levels of the Chemotherapeutic Drug, Paclitaxel, When Given Together as Part of a Treatment Regimen

Inclusion Criteria: * Confirmed diagnosis of a solid tumor that is refractory to standard therapies and is not amenable to treatment with established curative or palliative therapies and for whom paclitaxel and carboplatin is deemed an acceptable treatment by the investigator * Males or females ≥18 years of age * Life expectancy of ≥12 weeks * Minimum of 1 lesion * ECOG performance status of 0, 1 or 2 * Adequate bone marrow reserve * Adequate renal and liver function Exclusion Criteria: * Brain metastases that are symptomatic or require ongoing treatment * Major trauma or surgery within last 2 months, acute infection within 2 weeks (14 days), or radiotherapy, chemotherapy, immunotherapy or hormonal therapy within past 4 weeks * Persistent grade 2 or greater toxicity related to prior therapy * Grade 2 or greater peripheral neuropathy * Recent or current use of Cyp3A4, Cyp2C8 or P-gp inhibitors * Recent or current use of CYP enzyme inducers